- Home
- FSBC vs PRAX Comparison
FSBC vs PRAX Comparison
Compare FSBC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSBC
- PRAX
- Stock Information
- Founded
- FSBC 2002
- PRAX 2015
- Country
- FSBC United States
- PRAX United States
- Employees
- FSBC N/A
- PRAX N/A
- Industry
- FSBC Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FSBC Finance
- PRAX Health Care
- Exchange
- FSBC Nasdaq
- PRAX Nasdaq
- Market Cap
- FSBC 581.0M
- PRAX 599.7M
- IPO Year
- FSBC 2021
- PRAX 2020
- Fundamental
- Price
- FSBC $27.96
- PRAX $38.55
- Analyst Decision
- FSBC Buy
- PRAX Strong Buy
- Analyst Count
- FSBC 4
- PRAX 10
- Target Price
- FSBC $34.75
- PRAX $116.50
- AVG Volume (30 Days)
- FSBC 47.7K
- PRAX 320.6K
- Earning Date
- FSBC 07-23-2025
- PRAX 05-02-2025
- Dividend Yield
- FSBC 2.86%
- PRAX N/A
- EPS Growth
- FSBC N/A
- PRAX N/A
- EPS
- FSBC 2.27
- PRAX N/A
- Revenue
- FSBC $124,973,000.00
- PRAX $8,122,000.00
- Revenue This Year
- FSBC $26.96
- PRAX N/A
- Revenue Next Year
- FSBC $15.14
- PRAX N/A
- P/E Ratio
- FSBC $12.32
- PRAX N/A
- Revenue Growth
- FSBC 11.14
- PRAX 270.02
- 52 Week Low
- FSBC $22.22
- PRAX $26.70
- 52 Week High
- FSBC $35.13
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FSBC 48.82
- PRAX 53.72
- Support Level
- FSBC $27.26
- PRAX $35.21
- Resistance Level
- FSBC $28.57
- PRAX $38.90
- Average True Range (ATR)
- FSBC 0.68
- PRAX 2.09
- MACD
- FSBC -0.14
- PRAX 0.07
- Stochastic Oscillator
- FSBC 23.42
- PRAX 69.58
About FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.